ACRX AcelRx Pharmaceuticals, Inc.

2.60
-0.05  -1.89%
Previous Close 2.65
Open 2.65
Price To book 36.81
Market Cap 117.87M
Shares 45,333,000
Volume 175,413
Short Ratio 14.87
Av. Daily Volume 216,590

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515708
  2. 8-K - Current report 162047581
  3. 8-K - Current report 162026899
  4. 8-K - Current report 161969180
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161965874

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
NDA filing announced December 13, 2016.
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. Additional clinical trial initiated September 2016.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur
  2. AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
  3. AcelRx Pharmaceuticals Announces DSUVIA™ as Brand Name for ARX-04 in the United States
  4. The Story of AcelRx (ACRX), an Innovator in Developing & Commercializing Therapies for the Treatment of Acute Pain
  5. Does AcelRx Pharmaceuticals Inc (ACRX) Stack Up Against Its Peers?
  6. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : December 13, 2016
  7. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. AcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain
  9. AcelRx Pharmaceuticals Reports on ARX-04 Market and Landscape Presented at Analyst & Investor Event
  10. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  11. AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies for Treatment of Acute Pain
  12. Edited Transcript of ACRX earnings conference call or presentation 1-Nov-16 8:30pm GMT
  13. AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the Annual ASRA Pain Medicine Meeting
  14. AcelRx Pharmaceuticals to Host Analyst & Investor Event on December 1, 2016
  15. ACELRX PHARMACEUTICALS INC Financials
  16. AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in November
  17. ETF’s with exposure to AcelRx Pharmaceuticals, Inc. : November 4, 2016
  18. AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
  19. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

SEC Filings

  1. 8-K - Current report 17515708
  2. 8-K - Current report 162047581
  3. 8-K - Current report 162026899
  4. 8-K - Current report 161969180
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161965874
  6. 8-K - Current report 161916039
  7. 8-K - Current report 161903334
  8. 8-K - Current report 161890657
  9. 8-K - Current report 161886218
  10. 8-K - Current report 161829939